Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01831076 · ClinicalTrials.gov registry record · Phase 2
Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01831076 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 36 participants.
The verdict
NCT01831076, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This phase II trial studies how well exemestane before surgery works in treating postmenopausal patients with newly diagnosed estrogen receptor positive stage II-III breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by blocking the use of estrogen by the tumor cells.
Interventions
- DRUG Exemestane
- DRUG Exemestane and tamoxifen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2002-04 |
| Est. Completion | 2022-01-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01831076
The ClinicalTrials.gov registry entry for NCT01831076 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exemestane is the first listed.
NCT01831076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01831076 about?
NCT01831076 is a clinical study titled "Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors". This phase II trial studies how well exemestane before surgery works in treating postmenopausal patients with newly diagnosed estrogen receptor positive stage II-III breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by block...
What is the current status of trial NCT01831076?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2002-04. Estimated completion is 2022-01-06.
What interventions are being tested in trial NCT01831076?
The interventions under investigation include: Exemestane (DRUG), Exemestane and tamoxifen (DRUG).
Who is sponsoring clinical trial NCT01831076?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.